• Publications
  • Influence
Neuroblastoma: a disease requiring a multitude of imaging studies.
  • B. Kushner
  • Medicine
  • Journal of nuclear medicine : official…
  • 1 July 2004
Neuroblastoma stands out among pediatric solid tumors because of its relative frequency, intriguing natural history, prognostic biologic features, and therapeutic challenges. It is the most commonExpand
Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy.
PURPOSE To test intensive alkylator-based therapy in desmoplastic small round-cell tumor (DSRCT). PATIENTS AND METHODS Patients received the P6 protocol, which has seven courses of chemotherapy.Expand
Neuroblastoma metastatic to the central nervous system
The central nervous system (CNS) can be a sanctuary site for cancer cells, because the blood‐brain barrier impedes penetration of most chemotherapeutic agents. The authors hypothesized that, withExpand
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
Innovation in the management of brain metastases is needed. We evaluated the addition of compartmental intrathecal antibody-based radioimmunotherapy (cRIT) in patients with recurrent metastaticExpand
Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
PURPOSE To improve the prognosis of patients with poor-risk peripheral primitive neuroectodermal tumors (pPNETs; including peripheral neuroepithelioma and Ewing's sarcoma), while testing theExpand
The impact of gross total resection on local control and survival in high-risk neuroblastoma.
BACKGROUND/PURPOSE Gross total resection of the primary tumor in treatment of high-risk neuroblastoma remains controversial. Furthermore, there are few reports of the effect of primary tumorExpand
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.
PURPOSE Anti-GD2 murine IgG3 antibody 3F8 kills neuroblastoma cells by antibody-dependent cell-mediated cytotoxicity (ADCC). Granulocyte macrophage colony-stimulating factor (GM-CSF) enhancesExpand
Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity.
We have previously shown that 3F8, a murine IgG3, monoclonal antibody (MoAb) specific for the ganglioside GD2, mediates tumor cell kill in vitro and in vivo. We now describe receptor requirements ofExpand
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.
PURPOSE To improve the long-term event-free survival of patients with Ewing's family of tumors (EFTs) using high-dose, short-term chemotherapy. PATIENTS AND METHODS P6 was a prospective study ofExpand
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.
PURPOSE Anti-GD2 monoclonal antibody (MoAb) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown efficacy against neuroblastoma (NB). Prognostic variables that couldExpand